



## ADULT Medication Monograph

# MOXIFLOXACIN



This document should be read in conjunction with this [DISCLAIMER](#)

[Formulary: Restricted](#)

<b>Class</b>	Quinolone antibiotic
<b>Presentation</b>	<b>Infusion:</b> 400mg/250mL <b>Tablet:</b> 400mg
<b>Storage</b>	<b>Infusion</b> Store at 15 to 30°C. Do not refrigerate. The solution precipitates below 15 °C but will re-dissolve at room temperature
<b>Dose</b>	<b><u>Severe infections (where resistance or contraindications to other agents are present), Community acquired pneumonia</u></b> <b>Oral/IV:</b> 400mg once daily  <b><u>For second line treatment of mycoplasma genitalium in patients who have failed or are contraindicated to azithromycin under the direction of a sexual health physician</u></b> <b>Oral:</b> 400mg once daily (for 7 days as per eTG)  <b>All other use requires approval from a Clinical Microbiologist or Infectious Diseases Physician</b>
<b>Administration</b>	Refer to the <a href="#">Australian Injectable Drugs Handbook</a>  <b><u>IV Infusion</u></b> Infuse undiluted over 60 minutes (avoid bolus or rapid infusion)  <b><u>Oral:</u></b> Swallow whole. Do not take antacids, iron, magnesium or zinc within 2 hours of oral dose as absorption may be impaired

<b>Pregnancy</b>	<p><b>1<sup>st</sup> Trimester:</b> Consider alternative*</p> <p><b>2<sup>nd</sup> Trimester:</b> Consider alternative*</p> <p><b>3<sup>rd</sup> Trimester:</b> Consider alternative*</p> <p>*Maternal use of quinolones has not been associated with congenital malformations or adverse pregnancy outcomes. There are no published reports of moxifloxacin in pregnancy but it should not be withheld if it is the medication of choice.</p>
<b>Breastfeeding</b>	Considered safe to use
<b>Monitoring</b>	<p>May prolong the QT interval – do not use with other medications that prolong the QT interval</p> <p>Monitor for tendon pain (especially of the Achilles tendon), signs of hepatotoxicity and blood dyscrasias</p> <p>There is an association with the rare but serious adverse event of aortic aneurysm/dissection with the use of fluoroquinolone antibiotics. Please refer to the Medication Safety Alert</p>
<b>Clinical Guidelines and Policies</b>	<p><b>HDWA Policies:</b>  <a href="#">Medication Safety Alert - Fluoroquinolones and risk of aortic aneurysm/dissection</a></p> <p><b>WNHS Policies:</b>          WNHS Policy: <a href="#">Antimicrobial Stewardship</a></p> <p><b>KEMH Clinical Guidelines:</b>  <a href="#">Gynaecology (Non-oncological)</a></p> <p><b>KEMH Pharmaceutical &amp; Medicines Management Guidelines:</b>          KEMH Pharmaceutical &amp; Medicines Management Guideline:  <a href="#">Medication Administration</a></p>
<b>References</b>	<p>Australian Medicines Handbook. Moxifloxacin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Mar 25]. Available from: <a href="https://amhonline.amh.net.au/">https://amhonline.amh.net.au/</a></p> <p>MIMS Australia. Moxifloxacin. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2015 Mar 25]. Available from: <a href="https://www.mimsonline.com.au">https://www.mimsonline.com.au</a></p> <p>Society of Hospital Pharmacists of Australia. Moxifloxacin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2020 [cited 2020 Mar 25]. Available from: <a href="http://aidh.hcn.com.au">http://aidh.hcn.com.au</a></p> <p>Therapeutic Guidelines. Treatment of asymptomatic Mycoplasma</p>

	genitalium infection. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2019 [cited 2020 Mar 25]. Available from: <a href="https://tgdcdp.tg.org.au">https://tgdcdp.tg.org.au</a>
--	---

Keywords:	Moxifloxacin, avelox, CAP, community acquired pneumonia, severe infections, quinolone		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	March 2015	Version:	4.0
Last reviewed:	May 2020	Next review date:	May 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	Jan 2018
Standards Applicable:	NSQHS Standards: 3  Infection Control, 4  Medication Safety,		

**Printed or personally saved electronic copies of this document are considered uncontrolled.**

**Access the current version from the WNHS website.**

**For any enquiries relating to this guideline, please email [KEMH.PharmacyAdmin@health.wa.gov.au](mailto:KEMH.PharmacyAdmin@health.wa.gov.au)**

© Department of Health Western Australia 2020